Pre-exposure prophylaxis is cost-effective for HIV in the UK
Lancet Infect Dis
.
2018 Jan;18(1):10-11.
doi: 10.1016/S1473-3099(17)30594-7.
Epub 2017 Oct 17.
Authors
Paul Revill
1
,
Ellen Dwyer
2
Affiliations
1
Centre for Health Economics, University of York, York YO10 5DD, UK. Electronic address: paul.revill@york.ac.uk.
2
Berkshire Healthcare NHS Foundation Trust, Berkshire, UK.
PMID:
29054788
DOI:
10.1016/S1473-3099(17)30594-7
No abstract available
Publication types
Comment
MeSH terms
Anti-HIV Agents / economics*
Cost-Benefit Analysis
HIV
HIV Infections*
Homosexuality, Male
Humans
Male
Pre-Exposure Prophylaxis / economics*
Sexual and Gender Minorities*
United Kingdom
Substances
Anti-HIV Agents